Fortrea Holdings Inc. logo

Fortrea Holdings Inc.

FTRE

NASDAQHealthcareBiotechnology

Previous close

$18.39

+$0.20 · +1.10%

Aug 21, 4:00 PM ET

FTRE company overview

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

69

Gaining

Sentiment

49

Mixed

Risk resilience

48

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Anshul Thakral
Listed since
Jun 20, 2023
Employees
14,000

Market position

Day range

Current $18.39

52-week range

Current $18.39

Open
$18.19
Previous close
$18.19
Volume
864.12K
0.58× average
Average volume
1.48M
Average daily volume
Market cap
1.75B USD
Beta
1.97
Market reference 1
50-day average
$17.8864
+2.82% above average
200-day average
$14.2434
+29.11% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-19.77×
P/B (TTM)
3.31×
P/S (TTM)
0.65×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
17.11%
Operating margin
0.41%
Net margin
-3.18%

Financial health

Debt / equity
2.13×

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-9.74%
11 comparable reports
Latest EPS result
0.23
Estimate 0.18 · Beat by 27.49%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.40.230.06-0.11Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual 0.18, estimate 0.36, surprise -50.00%, Miss. Q2 2025, reported May 12, 2025: actual 0.02, estimate -0.07, surprise +128.57%, Beat. Q3 2025, reported Aug 6, 2025: actual 0.19, estimate 0.06, surprise +216.67%, Beat. Q4 2025, reported Nov 5, 2025: actual 0.12, estimate 0.16, surprise -25.00%, Miss. Q1 2026, reported Feb 26, 2026: actual 0.09, estimate 0.16, surprise -43.75%, Miss. Q2 2026, reported May 5, 2026: actual 0.16, estimate 0.03, surprise +433.33%, Beat. Q3 2026, reported Jul 29, 2026: actual 0.23, estimate 0.18, surprise +27.49%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.23, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates738.71M686.64M634.57M582.5MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual 697M USD, estimate 660.98M USD, surprise +5.45%, Beat. Q2 2025, reported May 12, 2025: actual 651.3M USD, estimate 610.91M USD, surprise +6.61%, Beat. Q3 2025, reported Aug 6, 2025: actual 710.3M USD, estimate 623.37M USD, surprise +13.94%, Beat. Q4 2025, reported Nov 5, 2025: actual 701.3M USD, estimate 665.22M USD, surprise +5.42%, Beat. Q1 2026, reported Feb 26, 2026: actual 660.5M USD, estimate 665.22M USD, surprise -0.71%, Miss. Q2 2026, reported May 5, 2026: actual 636.5M USD, estimate 628.51M USD, surprise +1.27%, Beat. Q3 2026, reported Jul 29, 2026: actual 678.2M USD, estimate 647.57M USD, surprise +4.73%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 670.51M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings
Strong buy00%
Buy542%
Hold650%
Sell18%
Strong sell00%

FTRE news

FTRE peers

ETFs holding FTRE

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research FTRE

research.disclaimer